HC Wainwright Issues Optimistic Forecast for XENE Earnings

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) – Equities research analysts at HC Wainwright lifted their Q2 2026 earnings per share estimates for shares of Xenon Pharmaceuticals in a report issued on Friday, May 8th. HC Wainwright analyst D. Tsao now forecasts that the biopharmaceutical company will post earnings of ($1.08) per share for the quarter, up from their previous estimate of ($1.26). HC Wainwright currently has a “Buy” rating and a $74.00 price target on the stock. The consensus estimate for Xenon Pharmaceuticals’ current full-year earnings is ($4.83) per share. HC Wainwright also issued estimates for Xenon Pharmaceuticals’ Q3 2026 earnings at ($1.10) EPS, Q4 2026 earnings at ($1.16) EPS, FY2026 earnings at ($4.52) EPS, FY2027 earnings at ($5.00) EPS, FY2028 earnings at ($4.03) EPS, FY2029 earnings at ($2.39) EPS and FY2030 earnings at ($0.37) EPS.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.17) earnings per share for the quarter, hitting analysts’ consensus estimates of ($1.17). During the same period last year, the company posted ($0.83) EPS.

A number of other equities research analysts have also recently weighed in on XENE. Guggenheim restated a “buy” rating and issued a $90.00 price target on shares of Xenon Pharmaceuticals in a research note on Monday, March 9th. Needham & Company LLC dropped their price target on Xenon Pharmaceuticals from $80.00 to $78.00 and set a “buy” rating on the stock in a research note on Friday. Stifel Nicolaus set a $66.00 price target on Xenon Pharmaceuticals in a research note on Tuesday, February 10th. Jefferies Financial Group set a $100.00 price objective on Xenon Pharmaceuticals in a report on Monday, March 9th. Finally, Deutsche Bank Aktiengesellschaft increased their target price on Xenon Pharmaceuticals from $56.00 to $90.00 and gave the stock a “buy” rating in a report on Tuesday, March 10th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $74.56.

Xenon Pharmaceuticals Stock Down 1.2%

Shares of Xenon Pharmaceuticals stock opened at $55.78 on Tuesday. Xenon Pharmaceuticals has a 12-month low of $28.19 and a 12-month high of $63.95. The business’s 50 day moving average is $55.09 and its 200-day moving average is $46.80. The stock has a market cap of $5.39 billion, a P/E ratio of -11.87 and a beta of 0.65.

Institutional Investors Weigh In On Xenon Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the company. Cinctive Capital Management LP boosted its position in shares of Xenon Pharmaceuticals by 1.1% during the fourth quarter. Cinctive Capital Management LP now owns 23,317 shares of the biopharmaceutical company’s stock valued at $1,045,000 after buying an additional 263 shares during the last quarter. Arizona State Retirement System raised its stake in shares of Xenon Pharmaceuticals by 1.8% in the third quarter. Arizona State Retirement System now owns 19,290 shares of the biopharmaceutical company’s stock valued at $774,000 after buying an additional 334 shares during the period. State of Wyoming raised its stake in shares of Xenon Pharmaceuticals by 30.4% in the fourth quarter. State of Wyoming now owns 1,501 shares of the biopharmaceutical company’s stock valued at $67,000 after buying an additional 350 shares during the period. Quarry LP raised its stake in shares of Xenon Pharmaceuticals by 25.0% during the 3rd quarter. Quarry LP now owns 2,500 shares of the biopharmaceutical company’s stock valued at $100,000 after purchasing an additional 500 shares during the period. Finally, Altfest L J & Co. Inc. raised its stake in shares of Xenon Pharmaceuticals by 6.5% during the 4th quarter. Altfest L J & Co. Inc. now owns 8,232 shares of the biopharmaceutical company’s stock valued at $369,000 after purchasing an additional 501 shares during the period. Institutional investors and hedge funds own 95.45% of the company’s stock.

Insider Buying and Selling at Xenon Pharmaceuticals

In other news, insider Christopher John Kenney sold 2,771 shares of the firm’s stock in a transaction dated Tuesday, March 10th. The stock was sold at an average price of $60.11, for a total transaction of $166,564.81. Following the completion of the transaction, the insider directly owned 4,729 shares in the company, valued at $284,260.19. This trade represents a 36.95% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Ian Mortimer sold 270,000 shares of the firm’s stock in a transaction dated Monday, March 9th. The stock was sold at an average price of $60.33, for a total value of $16,289,100.00. Following the transaction, the chief executive officer owned 6,000 shares of the company’s stock, valued at $361,980. This trade represents a 97.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 296,707 shares of company stock worth $17,845,365. 4.07% of the stock is currently owned by insiders.

More Xenon Pharmaceuticals News

Here are the key news stories impacting Xenon Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright lifted earnings estimates across several future periods, including FY2026, FY2027, FY2028, FY2029 and FY2030, signaling stronger outlook assumptions for Xenon Pharmaceuticals. Article Title
• Positive Sentiment: The firm reiterated a Buy rating and $74 price target, which is above the recent trading range and may reinforce investor optimism about upside potential. Article Title
• Neutral Sentiment: Despite the improved estimates, HC Wainwright still expects Xenon to post losses in the near term, with FY2026 EPS forecast at ($4.52) and consensus full-year EPS at ($4.83).
• Neutral Sentiment: Separate reports noted a sharp increase in short interest, but the reported short-interest figures were 0 shares, making the data difficult to interpret as a meaningful trading signal.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.